TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7771102
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration without current (procaine, flufenamic acid)
Study: 2178489
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and fentanyl (continuous infusion)
Study: 2178489
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and fentanyl (intermittent bolus injections)
Study: 2178489
Drug: Diazepam and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam and fentanyl (continuous infusion)
Study: 2178489
Drug: Diazepam and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam and fentanyl (intermittent bolus injections)
Study: 6777812
Drug: High Dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Dose (250 mg per week)
Study: 6777812
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose (12.5 mg per week)
Study: 26951309
Drug: Apitolisib 40
Normalized name: Apitolisib
DrugBank: Apitolisib (DB12180)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apitolisib 40 mg once per day
Study: 26951309
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg once per day
Study: 25027140
Drug: Hydroxychloroquine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (400 mg/d)
Study: 22236497
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg/day for 6 weeks)
Study: 19151659
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 x 1 g daily for 6 months
Study: 19151659
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (fluocortolone and topical prednisolone acetate)
Study: 6209832
Drug: Hemodilution therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodilution therapy (venesection of 250‐650 ml during the first 2 days and low‐molecular weight dextran administration)
Study: 29439736
Drug: Formula A
Normalized name: ACD-Solution Formula A
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Formula A (1.2 g/100 mL)
Study: 29439736
Drug: Formula B
Normalized name: Formula B
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula B (1.7 g/100 mL)
Study: 10647066
Drug: Test diet
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test diet with high soy protein and soluble fiber (12 +/- 2 g/d soy protein)
Study: 8346486
Drug: WEB 2086
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: WEB 2086 (100 mg three times a day)
Study: 3732901
Drug: 0.1 N
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 N hydrochloric acid infusion
Study: 3732901
Drug: 0.1 N
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.1 N hydrochloric acid infusion in patients without duodenal ulcer
Study: 21944168
Drug: High-intensity weight-lifting
Normalized name: chitosan high molecular weight (400-800 MPA.S)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity weight-lifting exercise and targeted multidisciplinary treatment
Study: 12055582
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral supplementation for 5 days with 1 L/day of a formula enriched with arginine, omega-3 fatty acids, and RNA (n = 102)
Study: 12055582
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral supplementation plus postoperative jejunal infusion with the same enriched formula (n = 101)
Study: 10606379
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% diclofenac in lecithin organogel
Study: 8695584
Drug: Diazepam (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (0.3 mg/kg) administered at home 60 minutes before treatment
Study: 8695584
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered at home 60 minutes before treatment
Study: 2064345
Drug: Tamoxifen (2x20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (2x20 mg/day)
Study: 2064345
Drug: Tamoxifen +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen + Prednisolone (3x2.5 mg/day)
Study: 6677080
Drug: Two-year primary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-year primary prevention program consisting of drug education, 'alternatives,' and affective in-service training for teachers.
Study: 30769293
Drug: No DHP‐PMX
Approvals — FDA: no, EMA: no, PMDA: no
Description: No DHP‐PMX therapy
Study: 25618970
Drug: Gushenyutai plaster
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gushenyutai plaster plus comprehensive therapy
Study: 25618970
Drug: Comprehensive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive therapy alone
Study: 15239288
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (5‐FU + leucovorin)
Study: 11559727
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment by surgeons treating more than 10 cases
Study: 7750185
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment skill of pause and regress in six parts
Study: 23135774
Drug: Tramadol (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (1.5 mg/kg within 0.9% saline solution)
Study: 23135774
Drug: Levobupivacaine (0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (0.25% in 0.9% saline solution)
Study: 17174704
Drug: Non-nucleoside reverse
Normalized name: Non-nucleoside reverse transcriptase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-nucleoside reverse transcriptase inhibitor (NNRTI) strategy (NNRTI plus NRTI; n=463)
Study: 17174704
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI) strategy (PI plus NRTI; n=470)
Study: 14601763
Drug: Sequential conditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential conditional probability ratio tests (SCPRTs)
Study: 10974295
Drug: Azithromycin (3‐day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (3‐day course, oral dose of 10 mg/kg per day)
Study: 10974295
Drug: Topical oxytetracycline/polymyxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxytetracycline/polymyxin ointment (twice a day for 2 months)
Study: 8792795
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of usual treatment (methotrexate, penicillamine, or sulfasalazine)
Study: 1621750
Drug: Loracarbef (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loracarbef (200 mg capsules twice a day or 15 mg/kg/day suspension)
Study: 1621750
Drug: Penicillin VK
Normalized name: PENICILLIN VK 250MG TAB
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin VK (250 mg capsules four times a day or 20 mg/kg/day suspension)
Study: 7113952
Drug: Treadmill exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill exercise (mild) increasing daily expenditure to 110% of sedentary expenditure
Study: 7113952
Drug: Treadmill exercise
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treadmill exercise (moderate) increasing daily expenditure to 125% of sedentary expenditure
Study: 7113952
Drug: Sedentary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedentary treatment
Study: 31475793
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with rivaroxaban plus a single antiplatelet agent
Study: 27775865
Drug: Everolimus plus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus plus low-dose tacrolimus (EVR+LTac)
Study: 23437144
Drug: 0.25 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 µg calcitriol per day
Study: 12153554
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with ursodeoxycholic acid (500 mg bid) and pravastatin (20 mg bid) for three weeks before cholecystectomy
Study: 12153554
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with ursodeoxycholic acid and pravastatin
Study: 9817157
Drug: Sharpened cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sharpened cut-off values and time- and treatment-specific PEFs
Study: 9817157
Drug: Morning peak
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning peak expiratory flow before any (bronchodilator) treatment
Study: 7543891
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose rate (HDR) conformal boost brachytherapy with 45.6 Gy whole pelvis external irradiation and three HDR fractions of 5.5 Gy each (18 patients) or 6 Gy each (15 patients) to the prostate.
Study: 2708231
Drug: Inhaled lipopolysaccharides
Normalized name: sulfated mucopolysaccharides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled lipopolysaccharides (LPS) from Escherichia coli 026:B6 (22.2-micrograms total dose)
Study: 2708231
Drug: Placebo procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo procedure (diluent substituted for LPS solution)
Study: 24833003
Drug: Liberal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal blood glucose management (BGM) (120-180 mg/dl)
Study: 24833003
Drug: Strict blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strict blood glucose management (BGM) (90-110 mg/dl)
Study: 21771085
Drug: scGOS/lcFOS mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: scGOS/lcFOS mixture (8 g/l)
Study: 2752698
Drug: Dyazide (triamterene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyazide (triamterene 50 mg and hydrochlorothiazide 25 mg)
Study: 331919
Drug: Cyclandelate (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclandelate (1200 mg daily) plus amitriptyline
Study: 29553435
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salts plus Zn sulphate (10 mg for children younger than 6 months; 20 mg for children aged 6 months and older)
Study: 29553435
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salts plus Zn sulphate
Study: 30324839
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration salts
Study: 27439082
Drug: Successful aging
Normalized name: casein, Lactococcus lactis cultured, aged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful aging intervention: weekly health education sessions for 6 months, then monthly.
Study: 22791092
Drug: Intratracheal lucinactant
Normalized name: lucinactant Intratracheal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intratracheal lucinactant (175 mg/kg)
Study: 20976802
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy using hexylaminolevulinate (HAL) and methylaminolevulinate (MAL)
Study: 12060470
Drug: Graphic analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graphic analysis using a* and L* values from reflectance spectrometer measurements.
Study: 2192454
Drug: 4 x
Normalized name: Mepilex AG 4 x 4"
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x 500 mg dimethylpolysiloxane (DPS)/24 hours
Study: 2192454
Drug: 2 x
Normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 x 500 mg dimethylpolysiloxane (DPS)/12 hours
Study: 28653424
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of anesthetic ointment (lidocaine/prilocaine‐AO)
Study: 22185749
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C (MMC) 0.4 mg/mL applied intraoperatively for 5 minutes
Study: 19821717
Drug: Haishengsu (2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haishengsu (2.4 mg, intravenously for 15 days)
Study: 9309996
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) at rest
Study: 9309996
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (NO) during exercise
Study: 24127448
Drug: Vintafolide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vintafolide (2.5 mg IV three times per week during weeks 1 and 3) plus PLD (50 mg/m(2) IV once every 28 days)
Study: 24127448
Drug: PLD alone
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD alone (50 mg/m(2) IV once every 28 days)
Study: 18182447
Drug: GH 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 0.8 mg/d
Study: 18182447
Drug: GH 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 1.6 mg/d
Study: 18182447
Drug: GH and
Normalized name: Cough And Cold
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH and DHEA (combination treatment)
Study: 16687344
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment (LLT) after CABG (group 1, n = 102, 49% male)
Study: 16687344
Drug: No lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: No lipid-lowering treatment (group 2, n = 107, 42% male)
Study: 11024215
Drug: ACEI (Angiotensin-Converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (Angiotensin-Converting Enzyme Inhibitor)
Study: 11024215
Drug: CCB (Calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCB (Calcium Channel Blocker)
Study: 30296325
Drug: Topical bromfenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical bromfenac 0.09% (12 eyes)
Study: 30296325
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 0.1% (12 eyes)
Study: 26412463
Drug: Vitamin B12
Normalized name: Vitamin B12
DrugBank: Cyanocobalamin Co-57 (DB09385)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin B12 (500 µg), Folic Acid (400 µg), and Vitamin D3 (600 IU) supplementation
Study: 19171089
Drug: Propofol controlled-infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol controlled-infusion at 1 microg/ml
Study: 19171089
Drug: Propofol controlled-infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol controlled-infusion at 2 microg/ml
Study: 19171089
Drug: Propofol controlled-infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol controlled-infusion at 3 microg/ml
Study: 19171089
Drug: Propofol controlled-infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol controlled-infusion at 4 microg/ml
Study: 19171089
Drug: Propofol controlled-infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol controlled-infusion at 5 microg/ml
Study: 15795184
Drug: Low-dose atropine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atropine (LDA) 2 microg/kg
Study: 12453930
Drug: Esmolol 1
Normalized name: esmolol 10 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol 1 mg kg(‐1) followed by 250 micro g kg(‐1) min(‐1)
Study: 8507448
Drug: Cortisol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (50 mg orally, 6 hourly on days 5 to 10) with placebo (Study A)
Study: 8507448
Drug: Cortisol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol (50 mg orally, 6 hourly on days 5 to 10) with atenolol (50 mg orally, 12 hourly on days 1 to 10) (Study B)
Study: 2886541
Drug: Intra-arterial dopamine
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial dopamine infusion after alpha-adrenoceptor blockade with phenoxybenzamine
Study: 2886541
Drug: Intra-arterial dopamine
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial dopamine infusion
Study: 2886541
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion after alpha-adrenoceptor blockade
Study: 2886541
Drug: Sulpiride (vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (vascular dopamine receptor antagonist)
Study: 31714470
Drug: FLS intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLS intervention with treatment including anti-osteoporosis medication.
Study: 30283014
Drug: Oral targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral targeted therapies (ibrutinib, idelalisib, venetoclax)
Study: 30283014
Drug: Next-generation anti-CD20
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Next-generation anti-CD20 monoclonal antibodies (obinutuzumab)
Study: 30283014
Drug: Programmed death
Normalized name: Magnetic nanocarrier-conjugated small interfering RNA against programmed death ligand 1
DrugBank: TTX-siPDL1 (DB18550)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Programmed death 1 inhibitors (pembrolizumab, nivolumab)
Study: 24879841
Drug: Sensor-augmented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-augmented therapy (control)
Study: 23503735
Drug: High-frequency chest
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency chest wall oscillation therapy
Study: 31856900
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine gluconate-impregnated patch
Study: 29268756
Drug: Allopurinol dose
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol dose escalation to achieve serum urate (SU) <6 mg/dl
Study: 21550556
Drug: Paclitaxel/Carboplatin (PC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel/Carboplatin (PC) - paclitaxel at a dose of 140 mg/m² and carboplatin AUC3, administered on days 1 and 15
Study: 21550556
Drug: Vinorelbine/Carboplatin (VC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine/Carboplatin (VC) - vinorelbine at a dose of 45 mg/m² orally and carboplatin AUC3, administered on days 1 and 15
Study: 10595478
Drug: Baseline (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline (no medication)
Study: 31918452
Drug: Apatinib 250
Normalized name: lapatinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib 250 mg once daily combined with EGFR-TKI
Study: 31188514
Drug: Pulsed Radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Radiofrequency (PRF) treatment for 6 minutes
Study: 28458049
Drug: Treatment-as-usual control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual control (n=47)
Study: 25967124
Drug: Tri-iodothyronine (T3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tri-iodothyronine (T3) treatment
Study: 18813917
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) injection (5 mug) into the tibialis anterior muscle
Study: 18813917
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline injection (0.5 ml, 5.8%) into the left and right TA
Study: 18813917
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection into the contralateral TA muscle
Study: 16307026
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) and chemotherapy
Study: 15001403
Drug: 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/kg of oral phenytoin (PO), divided in maximum doses of 400 mg every two hours
Study: 15001403
Drug: 18 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg/kg of intravenous phenytoin (IVP) at an initial infusion rate of 50 mg/min
Study: 15001403
Drug: 18 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 mg/kg of intravenous fosphenytoin (IVF) at an initial infusion rate of 150 mg/min
Study: 10698387
Drug: St Thomas
Approvals — FDA: no, EMA: no, PMDA: no
Description: St Thomas cardioplegic solution (Control)
Study: 17714967
Drug: GH 6
Normalized name: Zicam Cough 6 MG/ACTUAT Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 6 microg/kg/d (higher dose)
Study: 17714967
Drug: GH 3
Normalized name: Zicam Cough 3.3 MG/ACTUAT Oral Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH 3 microg/kg/d (low dose)
Study: 17225547
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine granules (1 package)
Study: 17225547
Drug: Duxil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duxil (1 tablet)
Study: 12953047
Drug: Prednisone at
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone at a dose of 60 mg/m2/day for 6 weeks, followed by 40 mg/m2/48 h for at least another 6 weeks
Study: 12953047
Drug: Cyclophosphamide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide (2 mg/kg/day for at least 8 weeks)
Study: 12953047
Drug: Alternate day
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate day therapy of prednisone
Study: 12953047
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and divided dosing of prednisone